Coverage
Filings
Genmab A/S announced encouraging results from its Phase 1/2 RAINFOL-01 trial for rinatabart sesutecan (Rina-S), an investigational antibody-drug conjugate (ADC), in heavily pretreated patients with advanced endometrial cancer.
| 22 Mar 2005 |
| Genmab, annual report | 18 Mar 2005 |
| Genmab, articles of association as per March 11, 2005 | 14 Mar 2005 |
| Genmab A/S, capital increase as a result of Employee Warrant Exercise | 11 Mar 2005 |
| Genmab A/S, current statement of shareholdings | 3 Mar 2005 |